PIN1, a perspective on genetic biomarker for nonalcoholic fatty liver disease (NAFLD)

Jing-Zhang Wang*,1, Yu-Hua Zhang 1, Jing Bai 1, Yan-Wei Liu, Wen-Tao Du**

Affiliated Hospital, College of Medicine, College of Life Sciences and Food Engineering, Hebei University of Engineering, Handan, 056038, PR China

ARTICLE INFO

Abstract

Objective: A novel genetic and molecular basis of nonalcoholic fatty liver disease (NAFLD) was explored. Study design: A 38-year-old male, who has no bad living and dietary habits, was diagnosed as NAFLD. The potential pathogenic role of Pin1 was evaluated by enzyme-linked immunosorbent (ELISA) assay and single nucleotide polymorphism (SNP) sequencing. Results: ELISA determined a six-time higher concentration of plasma Pin1 compared to our previous data. Nine PIN1 SNPs were sequenced and classified according to their NAFLD-pathogenic risks, suggesting that rs2233678 and rs2287839 may be the most important genotypes that result in Pin1 overexpression and NAFLD development. Conclusion: In summary, this work explores a novel basis for early-onset NAFLD and highlights that elevated plasma Pin1 may predict NAFLD risk at early stage. Hypothetically, inhibiting Pin1 may benefit NAFLD prevention in the future.

© 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Nonalcoholic fatty liver disease (NAFLD) is a major cause of liver fibrosis, liver cirrhosis and liver cancers, implying that early diagnosis of NAFLD will benefit the prevention of many liver diseases [1–4]. However, the pathogenic mechanisms of NAFLD are still complicated and even ambiguous until now, and recent studies increasingly emphasized the importance of genetic variations in the pathogenesis of NAFLD. For example, the polymorphisms of several genes such as adiponectin C1Q (ADIPOQ), patatin-like phospholipase domain-containing protein-3 (PNPLA3), Tribbles-1 (TRIB1), and vitamin D-related genes, may play crucial roles in development and progression of NAFLD [5–9].

Recently, we demonstrated the medical application of 3D-printing in liver surgeries and drug hepatotoxicity evaluation [10], and we also elucidated the indispensably important role Pin1 in several human diseases [11–13]. The PIN1 gene encodes the peptidyl-prolyl cis-trans isomerase Pin1, which is the only known enzyme that modulates the cis-trans configuration of pThr/pSer-Pro motifs in many signaling molecules [13]. Herein, we intend to elucidate the potential pathogenic role of Pin1 in NAFLD.

2. Methods

2.1. Patient investigation

A 38-year-old individual was enrolled in the first department of cardiology in the Affiliated Hospital of Hebei University of Engineering on May 21, 2018. The individual finished a standard questionnaire, signed the informed consent form, and the study was approved by the Ethical Committee of the Affiliated Hospital of Hebei University of Engineering.

2.2. Experimental measurements

5 mL peripheral blood was collected into an anticoagulant vacuum tube. The plasma and the blood cells were separated by centrifugation at 3000 rpm for 10 min and were stored at ~80°C. The Pin1 concentration in the blood and the single nucleotide polymorphisms (SNPs) of the PIN1 gene were analyzed by ELISA.
(Human Pin1 ELISA kit, Product number: ZC1 BIO ZC-32747, Shanghai) [11] and DNA sequencing (Sangon Biotech, Shanghai), respectively. The reagents, primers for PCR, and DNA sequencing methods were provided by the Sangon Biotech (Shanghai) and shown in the Supplementary Material.

3. Results

The young individual (170 cm, 75 kg), who lives in the city of Handan and works in an office, was diagnosed with NAFLD in the Affiliated Hospital of Hebei University of Engineering. The triglyceride concentration in the individual’s blood was 3.65 mmol/L, which is much higher than the healthy value range (0.48–1.88 mmol/L). Fatty liver was further confirmed by liver imaging via computer tomography.

A questionnaire survey manifested that the individual has no bad living and dietary habits such as drinking, smoking, working overtime, staying up late, excessive intake of egg, meat, milk and fish, etc. The individual has no hypertension and diabetes, and his body mass index (25.9) is approximately in the normal range.

Based on the above information, the underlying NAFLD-pathogenic mechanism for the individual is not clear. Consequently, the physicians and researchers thus suggested a molecular and genetic analysis for the individual, focusing on the concentration of Pin1 protein in the blood and the single nucleotide polymorphisms (SNPs) of PIN1 gene.

The ELISA result indicated that the Pin1 concentration in the individual’s blood plasma (303.113 pg/mL) is significantly higher (about six-time more) than our previous determination of Pin1 concentration (about 50 pg/mL) in eleven volunteers [11]. The ELISA result indicated that the Pin1 concentration in the individual’s blood plasma (303.113 pg/mL) is significantly higher (about six-time more) than our previous determination of Pin1 concentration (about 50 pg/mL) in eleven volunteers [11].

High Pin1 in plasma may be due to enhanced PIN1 transcription due to genetic polymorphisms. Among the nine SNPs (Fig. 1), the PCR primers were not shown here because of word count limitation, the Pin1 high-expression genotypes as well as the high NAFLD-pathogenic risks were mainly attributed to rs2233678 and rs2287839 in the PIN1 gene promoter. For example: i. The SNP rs2233678 (NO. 2 in Fig. 1) was the –842GG homogeneous genotype, and –842G was proven to promote PIN1 transcription and enhance Pin1 expression (in some cancer patients) when compared with the –842C allele [14]; ii. The SNP rs2287839 (NO. 1) was the –5185GC heterogeneous genotype, and the variant –5185C has a lower affinity with AP4 (a PIN1 promoter suppressor) and thus may enhance PIN1 transcription (in some Alzheimer patients) when compared with the –5185G allele [15]; iii. The impacts of other SNPs (located in the promoter or exon 2 or introns), on PIN1 transcriptional efficiency, mRNA splicing and protein expression still need to be further elucidated. For example, the SNP rs2233679 (NO. 3) was identified as the –667CC homogeneous genotype in the promoter of PIN1 gene, but the influences of –667C and –667T on Pin1 expression and relevant diseases are still not very identical, necessitating further clinical investigations especially in different ethnic groups [16–19].

These pathogenic analysis collectively supports a hypothesis that higher PIN1 transcription and higher Pin1 expression might contribute to an increased risk of NAFLD in young human individuals.

4. Discussions

Considering that Pin1 regulates a series of signaling molecules in vivo [13], we speculate that Pin1 may promote the development of NAFLD by the following signaling pathways:

1. Nakatsu et al. firstly demonstrated that over-expressed Pin1 is necessary for methionine choline-deficient diet-induced NAFLD and the subsequent liver fibrosis in mice, whereas Pin1 knock-out mice were extremely resistant to these diseases [1].

2. Yang et al. found that Pin1 is up-regulated in mouse fibrotic liver tissues, that Pin1 plays a key role in dimethylnitrosamine-induced liver fibrosis in mice, and that Pin1 inhibition alleviates dimethylnitrosamine-induced liver fibrosis in mice, and these results may be partially due to the up-regulation of transforming growth factor-β1 (TGF-β1)-mediated fibrogenesis signalings induced by Pin1 [20].

3. The reduced activity of peroxisome proliferator-activated receptor α (PPARα) contributes to NAFLD, whereas enhancing PPARα activity ameliorates NAFLD [11]. Pin1 suppresses the expression levels of PPARα thus possibly resulting in NAFLD, but Pin1 knock-out mice are extremely resistant to NAFLD possibly because of enhanced PPARα expression and its downstream genes [1].

4. Pin1 is necessary for the activation of hepatic NF-κB and is important for the binding of NF-κB with DNA in hepatocytes [1,21]. Furthermore, the activation of NF-κB and its downstream inflammatory cytokines may aggravate NAFLD and liver fibrosis [1,21].

5. Compared to the wild-type mice, Pin1 knock-out mice had fewer fat tissues, which may be attributed to the insulin-signal-transduction mediated by Pin1 [22]. Pin1 enhanced the differentiation of mouse embryo fibroblasts into adipose cells in response to insulin stimulation, signifying that Pin1 may contribute to the obesity-related NAFLD [22].

[Image 94x67 to 491x225]

Fig. 1. The gene information of PIN1 and the genotypes of SNP sequencing data. Annotation: ‘+’ means the predicted NAFLD-pathogenic risk.
Besides, Pin1 may also contribute to NAFLD development by up-regulating hypoxia inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF), etc. [2,25,26].

5. Conclusion

In summary, the above descriptions primarily elicit the hypothesis that over-expressed Pin1 may play a harmful role in NAFLD, highlighting that Pin1 may be an important diagnostic biomarker and a potential therapeutic target for NAFLD and other relevant liver diseases. Predictably, PIN1 genotyping could be effective for screening high NAFLD-risk individuals, and Pin1 inhibitors (extracted from natural plants or chemically-synthesized) may have therapeutic efficacy for early NAFLD, thus preventing the development of many fatty liver-related diseases.

Additionally, a recent study found that alcohol stimulates Pin1 over-expression in mouse heart cells [27]. This finding probably supports the speculation that Pin1 may also play a critical pathogenic role in alcoholic fatty liver disease. Nevertheless, we should be clearly aware that large-cohort studies should be necessary to confirm the above predictions, especially when considering that only one patient with NAFLD was included in this short report, and we will try to elucidate them more strictly step by step in the future.

Conflicts of interest

None.

Funding

This work is supported by the funding from Hebei Provincial Department of Science and Technology of China (No. 182777107D) and the Hebei Provincial Social Science Fund Projects (No. HB19SH020; No. 201903041038).

Acknowledgements

The authors sincerely thank all the doctors of the first department of cardiology in the Affiliated Hospital of Hebei University of Engineering.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.metop.2019.100014.

References

[1] Nakatsu Y, Otani Y, Sakoda H, Zhang J, Guo Y, Okubo H, et al. Role of pin1 protein in the pathogenesis of nonalcoholic steatohepatitis in a rodent model. J Biol Chem 2012;287:44526–35.
[2] Novo E, Cannito S, Paternostro C, Bocca C, Miglietta A, Farola M. Cellular and molecular mechanisms in liver fibrogenesis. Arch Biochem Biophys 2014;548:20–37.
[3] Dalamaga M, Liu J. Mitochondrial glycerol 3-phosphate dehydrogenase deficiency aggravates hepatic triglyceride accumulation and steatosis. Metab Open 2019:100004.
[4] Cree-Green M, Ravi S, Carreau A-M, Sewell R, Baumgartner A, Cee G, et al. Nonalcoholic fatty liver disease in obese adolescent females is associated with multi-tissue insulin resistance and visceral adiposity markers. Metab Open 2015;2:100011.
[5] Jain V, Kumar A, Ahmad N, Jana M, Kaliavani M, Kumar B, et al. Genetic polymorphisms associated with obesity and non-alcoholic fatty liver disease in Asian Indian adolescents. J Pediatr Endocrinol Metab 2019;32:749–58.
[6] Targher G, Mantovani A, Aliu A, Mosca A, Panera N, Byrne CD, et al. Relationship between PNPLA3 rs738409 polymorphism and decreased kidney function in children with NAFLD. Hepatology 2019;70:142–53.
[7] Arai T, Asukawa M, Tsutoba A, Koeda M, Yoshida Y, Okubo T, et al. Association of vitamin D levels and vitamin D-related gene polymorphisms with liver fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease. Dig Liver Dis 2019;51:1036–42.
[8] Liu MW, Liu S, Shang MK, Liu XP, Wang Y, Li Q, et al. Association between ADIPOQ G276T and C1137G polymorphisms and the risk of non-alcoholic fatty liver disease: an updated meta-analysis. Mol Genet Genom Med 2019;7.
[9] Liu Q, Xue F, Meng J, Liu SS, Chen LZ, Gao H, et al. TRIB1 rs17321515 and rs2954029 gene polymorphisms increase the risk of non-alcoholic fatty liver disease in Chinese Han population. Lipids Health Dis 2019;18.
[10] Wang GZ, Xiong NY, Zhao LZ, Hu JT, Kong DC, Yuan JY. Review. J Surg 2018;36:1–6.
[11] Wang JZ, Bai J. New evidence to elucidate the controversial Pin1 concentration in human serum. J Clin Neurosci 2018;53:282–3.
[12] Wang J-Z, Zhang Y. Configuration-specific immunotherapy targeting cis-Thr231-Pro232 tau for Alzheimer disease. J Neurol Sci 2015;348:253–5.
[13] Wang J-Z, Liu B-G, Zhang Y. Pin1-based diagnostic and therapeutic strategies for breast cancer. Pharmacol Res 2015;93:28–35.
[14] Lu J, Yang L, Zhao H, Liu B, Li Y, Wu H, et al. The polymorphism and haplotypes of PIN1 gene are associated with the risk of lung cancer in southern and eastern Chinese populations. Hum Mutat 2011;32:1299–308.
[15] Ma SL, Tang NL, Tam CW, Lui VW, Lam LC, Chiu HF, et al. A PIN1 polymorphism that prevents its suppression by AP4 associates with delayed onset of Alzheimer’s disease. Neurobiol Aging 2012;33:804–13.
[16] Zeng LY, Luo SQ, Li X, Lu MX, Li HH, Li T, et al. Functional PIN1 promoter polymorphisms associated with risk of nasopharyngeal carcinoma in Southern Chinese populations. Sci Rep 2017;7:4593.
[17] Zeng LY, Huang GL, Luo SQ, Fu XX, Liao D, Li HH, et al. Association of PIN1 promoter polymorphisms with colorectal cancer risk and clinicopathological parameters. Int J Clin Exp Pathol 2016;9:9619–24.
[18] Zhu YM, Liu JW, Xu Q, Yuan Y. Pin1 promoter rs2233678 and rs2233679 polymorphisms in cancer: a meta-analysis. Asian Pac J Cancer Prev 2013;14:5965–72.
[19] You Y, Deng J, Zheng J, Jiang L, Li N, Wu H, et al. Functional polymorphisms in PIN1 promoter and esophageal carcinoma susceptibility in Chinese populations. Mol Biol Rep 2013;40:829–38.
[20] Yang J-W, Hien TT, Lim SC, Jun DW, Choi HS, Yoon JH, et al. Pin1 induction in the fibrotic liver and its roles in TGF-beta1 expression and Smad2/3 phosphorylation. J Hepatol 2014;60:1235–41.
[21] Kuboki S, Saito N, Clarke C, Schuster R, Blanchard J, Edwards MJ, et al. The peptideyl-prolyl isomerase, Pin1, facilitates NF-kappa B binding in hepatocytes and protects against hepatic ischemia/reperfusion injury. J Hepatol 2009;51:296–306.
[22] Uchida T, Furumai K, Fukuda T, Akiyama H, Takezawa M, Asano T, et al. Prolyl isomerase Pin1 regulates mouse embryonic fibroblast differentiation into adipose cells. PLoS One 2012;7:e311823.
[23] Lin N, Chen S, Pan W, Xu L, Hu K, Xu B, NP603, a novel and potent inhibitor of FGR1 tyrosine kinase, inhibits hepatic stellate cell proliferation and ameliorates hepatic fibrosis in rats. Am J Physiol Cell Physiol 2011;301:C649–77.
[24] Yoon W-J, Cho Y-D, Kim W-J, Bae H-S, Islam R, Hwang SW, Kang KW. Induction of vascular endothelial growth factor by peptidyl-prolyl isomerase Pin1 in breast cancer cells. Biochem Biophys Res Commun 2008;369:547–53.
[25] Lonati E, Brambilla A, Milani C, Masserini M, Palestini P, Bulbarelli A. Pin1, a new player in the fate of HIF-1 alpha degradation: an hypothetical mechanism inside vascular damage as Alzheimer’s disease risk factor. Front Cell Neurosci 2014;8:1.
[26] Wang Y, Li Z, Zhang Y, Yang W, Sun J, Shan L, et al. Targeting Pin1 protects mouse cardiomyocytes from high-dose alcohol-induced apoptosis. Oxidative Med Cell Longev 2016;2016:4528906.